Business
Theraclion Announces the Launch of a Capital Increase Through the Issuance of ABSA (Shares With Share Warrants Attached), With Preferential Subscription Rights for Existing Shareholders, for a Gross Amount of €6 Million, Secured by Subscription...
MALAKOFF, France, April 20, 2026--Regulatory News: Theraclion Announces the Launch of a Capital Increase Through the Issuance of ABSA (Shares With Share Warrants Attached), With Preferential Subscription Rights for Existing Shareholders, for a Gross Amount of €6 Million, Secured by Subscription Commitments Totalling €4.5 Million
About this update from Theraclion Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":375,"url":"https://media.zenfs.com/en/business-wire.com/81312596e8935104904e0ef22c41880c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IGysXNZUyyWtywUyoIO0sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/81312596e8935104904e0ef22c41880c","width":960,"height":360},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xgdjItUsqFuVKuLVzm6AUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NTA-/https://media.zenfs.com/en/business-wire.com/81312596e8935104904e0ef22c41880c","width":1000,"height":375}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Subscription price: €0.48 per share, representing a nominal discount of 3.52% to the closing share price as of April 17, 2026, and a discount of 8.60% when taking into account the theoretical value of one BSA","length":208,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Subscription ratio: 7 ABSAs for 34 existing shares","length":50,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Exercise parity of BSAs: 3 BSAs for 1 new share at an exercise price of €0.48","length":77,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Trading period for preferential subscription rights: from April 22 to May 4, 2026 inclusive","length":91,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Subscription period: from April 24 to May 6, 2026 inclusive","length":59,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Capital increase secured by subscription commitments for a total amount of €4.5 million, representing 75% of the transaction","length":124,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Potential capital increase of up to €8 million upon full exercise of all BSAs","length":77,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Investment eligible for the article 150-0 B ter of the French General Tax Code (reinvestment of capital gains)","length":110,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Theraclion securities eligible for PEA and PEA PME‑ETI schemes","length":62,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":858,"olType":false},{"type":"text","cont...